In this episode of Compound Wisdom, Steve Suid sits down with technologist and scientist Philippe Kahn—the inventor behind the first mobile photo sent over the internet and a pioneer of real-time photo sharing. Philippe shares how a personal challenge with his daughter’s sleep sparked the creation of Fullpower’s sleep-tracking technology, which has now captured hundreds of millions of nights of data. The conversation dives into what large-scale, longitudinal sleep data reveals about health, how AI is transforming sleep science and remote monitoring, practical habits that improve sleep quality, and why Darwin’s idea of adaptability matters for both biology and business.

In this episode of Compound Wisdom, we sit down with Dr. James Lavelle, a clinical pharmacist, board-certified clinical nutritionist, bestselling author of Cracking the Metabolic Code, and a leading authority on peptides and metabolic health.

We explore why the traditional medical system often misses root causes, how peptides and GLP-1 therapies should be used responsibly, and why bloodwork, lifestyle, and hormone balance are essential for longevity and performance.

• Why aging doesn’t have to mean physical decline
• How peptides actually work and why sourcing matters
• The difference between research-only peptides and human-use peptides
• The right way to approach GLP-1s for weight loss and metabolic health
• What causes “Ozempic face” and how to avoid it
• How The Metabolic Code identifies your biggest metabolic roadblocks
• When bloodwork, HRT, and TRT make sense for men and women

Dr. James Lavelle is a clinical pharmacist, board-certified clinical nutritionist, bestselling author, and founder of The Metabolic Code. With over 40 years in healthcare, he is widely recognized as a pioneer in integrative, regenerative, and peptide-based medicine.

• Cracking the Metabolic Code — Dr. James Lavelle
• The Metabolic Code framework
• Peptides discussed: BPC-157, Sermorelin, KPV, GHK-Cu
• GLP-1 medications: Ozempic, Mounjaro

This episode is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting peptides, GLP-1 medications, hormone therapy, or any medical treatment.

Episode Summary

Can AI really replace doctors, or is it simply changing how medicine is delivered?

In this episode of Compound Wisdom, Dr. Sean Arora shares a blunt, experience-driven perspective on AI in healthcare, why he left traditional hospital medicine after COVID, and how physician-led telehealth and preventative care are shaping the future of modern medicine.

Guest

Dr. Sean Arora — Physician licensed in all 50 U.S. states, Founder of Arora Health Group, specializing in telehealth, preventative medicine, HRT, peptides, and regenerative health.

Key Topics Covered

• Can AI replace doctors, or only assist them?
• Why traditional healthcare fails at prevention
• Leaving hospital medicine after COVID
• Telehealth done right vs. dangerous shortcuts
• HRT for men vs. women and why customization matters
• Peptides, GLP-1s, and Ozempic: hype vs. reality
• The risks of social-media medical advice
• Why lab work is the foundation of longevity care
• Ethical and regulatory risks in modern telehealth

Resources Mentioned

• Telehealth & preventative medicine platforms
• Hormone Replacement Therapy (HRT)
• Peptides & regenerative therapies
• GLP-1 medications (Ozempic, Mounjaro)
• Wearable health data (Oura, Whoop)

Disclaimer

This episode is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting or changing any medical treatment.

“You don’t need to leave the U.S. to get real stem cell therapy.” – Seth Berge

In this episode of Compound Wisdom, Steve Sood sits down with Seth Berge, founder of Regenerative Revival, to unpack what’s really holding back regenerative medicine—and why the problem isn’t the science, but the system delivering it.

Seth shares his unconventional path from high-ticket direct-to-consumer sales into the stem cell space, revealing how real demand and promising outcomes were being undermined by friction, poor communication, and broken follow-up models. Together, they explore how education-first selling, concierge care, and compliant systems can dramatically improve patient outcomes while still allowing the business to scale.

The conversation dives deep into stem cell myths, why leaving the U.S. for treatment is often unnecessary, and how regulation—when done right—can actually become a competitive advantage. Seth also explains the growing role of IV stem cells and exosomes in wellness, longevity, and inflammation support, along with where the regenerative health industry is heading next.

1. Friction in healthcare kills trust, outcomes, and conversion
2. 
   
3. Great medicine often fails because of broken delivery systems
4. 
   
5. Education-first models outperform traditional clinic selling
6. 
   
7. Stem cells can be explained without medical jargon
8. 
   
9. You don’t need to leave the U.S. for legitimate stem cell access
10. 
    
11. FDA “non-approval” does not mean illegal or ineffective
12. 
    
13. Cultured and expanded cells overseas carry unknown risks
14. 
    
15. IV stem cells and exosomes are emerging wellness tools
16. 
    
17. Concierge, mobile care improves patient experience and scale
18. 
    
19. Regulation can eliminate bad actors and reward compliant operators
20. 
    

00:01 Friction Kills Conversion

02:07 Seth’s Entry Into Stem Cells Through Sales

04:13 Full Rooms, Zero Conversions

05:42 Removing Friction From the Model

06:22 Why Dinner Seminars Still Work

09:12 Stem Cells Explained Simply

11:14 The Overseas Stem Cell Myth

13:47 Cultured Cells vs Non-Manipulated Tissue

15:42 Marketing Limits in the U.S.

17:01 IV Stem Cells and Exosomes

19:31 How Often to Use Stem Cells for Optimization

20:24 Pricing, Access, and Market Maturity

22:30...

“Doctors don’t have the training or the tools to help what she’s going through.” – Matthew Stern

In this episode of Compound Wisdom, Steve Sood sits down with Matthew Stern, founder of MyStart Health, to break down what’s actually changing inside telehealth—and why GLP-1s are only the beginning.

Matthew shares how he spent 20 years building businesses through digital marketing and full-funnel “customer journey” systems, then applied that same growth discipline to healthcare. He explains how MyStart scaled to 13,000 patients, why the business unexpectedly became 85% women (mostly 50+), and what he learned once he got deeper into the realities of doctors, pharmacies, and personalized medication protocols.

The conversation turns personal as Matthew describes his mom’s menopause experience, his wife’s postpartum hormone journey, and the recurring pattern many patients face: “your labs look great” while they still don’t feel right. From HRT and women’s hormone care to microdosing GLP-1s, blood work-driven longevity, and the “Wild West” of research peptides, this episode maps where modern healthcare is failing—and where telehealth is quietly heading next.

Takeaways

Access and affordability are the real bottlenecks in healthcare

MyStart scaled to 13,000 patients after launching last August

GLP-1s are expanding beyond weight loss into broader health use cases

Most of MyStart’s patients are women over 50 (about 85%)

Hormone health demand is rising, but many doctors aren’t trained for it

“Your bloodwork is fine” doesn’t always match how patients feel

High-cost concierge protocols create a massive gap in access

Microdosing GLP-1s is growing and isn’t only about losing weight

Blood work is the entry point to personalized longevity care

Some telehealth is “set it and forget it”—but follow-up changes outcomes

Research peptide sites can be risky compared to compliant pharmacy partners

Telehealth adoption is early—and Matthew sees 10–20x growth ahead

Chapters

00:01 Matthew’s 20-Year Growth Background (Digital Marketing + Customer Journey)

01:09 First Entry Into Telehealth (2015) and the “Lightbulb Moment”

02:20 Why He Went All-In and Acquired a Telehealth Platform

03:05 The GLP-1 Wave and Why the Industry Hasn’t “Evolved” Much

03:23 MyStart Growth: 13,000 Patients + What It Took to Get There

03:42 Early Startup Reality: Getting “Kicked” Until the Model Clicked

04:31 Why MyStart Became a Women-First Audience (85% Women, Mostly 50+)

05:56 HRT + Women’s Health: The Generational Impact of Past Medical Guidance

07:34 “Sorry, There’s Nothing We Can Do” — Mom’s Menopause Experience

08:04 Postpartum Reality: “Do I Get My Brain Back?” and the System Gap

09:24 The $6K–$8K Protocol Problem and Why Access Is Limited

10:34 Access + Affordability: $1,000–$1,400 vs $200–$300 per Month

12:10 GLP-1s Beyond BMI: Mental Health, Prevention, and Emerging Benefits

13:09 Microdosing GLP-1s: What People Miss (and Matthew’s Experience)

14:44 Blood Work + Longevity: Personalization as the Next Layer

16:30 Doctors Who “Check the Box” vs Doctors Who Actually Personalize Care

19:12 The Wild West: Research Peptides, Compliance, and Pharmacy Standards

22:19 Where Telehealth Is Heading in 2–5 Years (Cost Curves + New Meds)

25:12 Learning From Competitors: Pricing Models + Personalization Systems

26:35 The Question for the Next Guest: What Would You Change in Telehealth?

“Telehealth is not ideal for everything.” – Dr. Sajad Zalzala

In this episode of Compound Wisdom, Steve Sood sits down with Dr. Sajad Zalzala of Root Causes Medical to unpack what longevity medicine actually looks like when you move beyond “wait until you’re sick, then treat.”

Dr. Zalzala shares how he started in computer science, nearly left medical school, and ultimately moved toward functional, holistic, and integrative medicine after realizing traditional care often defaults to “cut it out” or “block it.” From there, a migraine patient became his telehealth “lightbulb moment,” leading him into the early telehealth world (2016–2017), where doctors were often building the protocols and infrastructure as they went.

The conversation then goes deep on today’s longevity landscape: why peptides are misunderstood, why women’s HRT is being re-evaluated after years of fear-driven headlines, why TRT injections can become a long-term commitment for men, and why stem cells still feel like a gray-zone “Wild West” without consistent outcomes data. Dr. Zalzala also introduces his Optional Aging Academy and the “seven drivers of aging” framework—built to make aging science more actionable for real people.

1. Dr. Zalzala started in computer science before switching to medicine.
2. 
   
3. He nearly dropped out of medical school early on.
4. 
   
5. Traditional care can become “cut it out or block it” too often.
6. 
   
7. Functional medicine focuses more on prevention and root causes.
8. 
   
9. A migraine case triggered his telehealth lightbulb moment.
10. 
    
11. Early telehealth had very little infrastructure in 2016–2017.
12. 
    
13. Doctors helped build protocols, documentation, and EMR workflows.
14. 
    
15. Telehealth isn’t for every case, but it can deliver focused, consistent care.
16. 
    
17. Peptides are often misunderstood and not the same as “peptides” people mean online.
18. 
    
19. The Women’s Health Initiative headlines shaped years of fear around HRT.
20. 
    
21. HRT for women is gaining traction again, with emphasis on proper dosing.

“PRP contains everything the body needs to regenerate.” – Giuseppe Calloni

In this episode of Compound Wisdom, Steve Sood sits down with Giuseppe Calloni of RegenLab USA to break down what platelet-rich plasma (PRP) really is, how it’s made, and why Giuseppe believes the future of regenerative medicine is prevention—not just treatment.

Giuseppe shares a non-linear career path that starts in Milan, moves through a PhD in atomic physics in the UK, and spans oil & gas, chemical R&D, and biotech before he ultimately lands in regenerative medicine and becomes CEO. That “career without a plan” theme becomes a key thread: curiosity, learning, and global experience across France, Switzerland, China, and the U.S. shaped how he thinks about science, products, and patients.

From there, the conversation gets practical. Giuseppe explains RegenLab’s gel separation technology in simple terms: blood is drawn into a tube containing a specialized gel, spun in a centrifuge for about five minutes, and separated by density into layers—allowing clinicians to create platelet-rich plasma. He also highlights that PRP has existed for decades, expanding from early uses into sports medicine, injuries, hair restoration, aesthetics, gynecology, and orthopedics.

The episode then shifts into what makes RegenLab different in Giuseppe’s view: a data-first approach (patents, clinical data, publications) and a long-term strategy to navigate global regulation. Giuseppe describes the reality of waiting years for approvals—including a 10-year FDA timeline that eventually led to a PRP-based kit for diabetic chronic wounds being released with nationwide reimbursement. He argues the delays are frustrating but necessary if the goal is safety, efficacy, and real patient outcomes.

Finally, Steve and Giuseppe go wider: exosomes, stem cells, and the “hype cycle” in longevity. Giuseppe is candid about how exosomes became popular as a concept, but questions whether many products in the market are truly data-driven. He also explains why RegenLab stays focused on PRP and its next evolution—PRP plus tissue engineering approaches like hyaluronic acid scaffolds, and new minimally invasive implant ideas using electrospinning and 3D printing to help patients recover faster and avoid major surgeries. The throughline is clear: keep people moving, keep quality of life high, and prevent the decline before it becomes irreversible.

Takeaways

Giuseppe’s career path started in Milan and led to a PhD in atomic physics in the UK.

Curiosity drove him across oil & gas, chemical R&D, and then biotech.

He worked across Italy, France, Switzerland, China, and the U.S. before settling in America.

He became CEO at RegenLab after a collaboration that began when RegenLab was a client.

RegenLab is positioned as a science-based medical device company (patents, publications, clinical data).

PRP is created by separating blood components by density using a specialized gel + centrifuge process.

The gel transitions state under spinning, allowing clean layer separation in about five minutes.

After separation, the platelet concentration can be increased by inverting the tube multiple times.

PRP has been used in the market since the 1970s and expanded into many clinical applications.

Use cases discussed include sports injuries, pain relief, hair loss, aesthetics, gynecology, and knee osteoarthritis.

Giuseppe claims PRP can regenerate at the cellular level via growth factors in platelets.

He says PRP is the only truly effective hair regeneration treatment currently.

RegenLab’s PRP platform includes “PRP plus” approaches and tissue engineering directions.

Combining PRP with hyaluronic acid can act as a scaffold and prolong time between treatments.

Giuseppe emphasizes prevention as the core direction of regenerative medicine.

RegenLab expanded...